Search
Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationaltherapy to diet and exercise in the management of 2 diabetes (T2DM). … It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665]
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalIt irreversibly binds to the active site of the enzyme resulting in permanent inhibition. … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal
Metaraminol
go.drugbank.com/drugs/DB00610ApprovedIt has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.
Categories: Adrenergic alpha-1 Receptor AgonistsIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Categories: Agents to Treat Airway Disease, Adrenergic beta-2 Receptor AgonistsBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia … due to non-selective steroidal activities [A275513, A275514].
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalThe development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin … Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746ApprovedIt was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder. … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalMore specifically, idebenone is thought to transfer electrons directly to complex III of the mitochondrial ETC, thereby circumventing complex I and restoring cellular energy (ATP) generation [L885]. … the lipid membrane and mitochondria from oxidative damage [A19768].
Alosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnIn June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured
Categories: Serotonin Receptor Antagonists, Serotonin 3 Receptor AntagonistsSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]